Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine
Top Cited Papers
- 15 April 2021
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 384 (15), 1468-1470
- https://doi.org/10.1056/nejmc2102179
Abstract
The mRNA-1273 vaccine against SARS-CoV-2 elicited high neutralizing-antibody titers in phase 1 trial participants1,2 and has been shown to be highly efficacious in preventing symptomatic Covid-19 disease and severe disease.3 The recent emergence of SARS-CoV-2 variants in the United Kingdom (the B.1.1.7 lineage) and in South Africa (the B.1.351 lineage) has led to concerns about increased transmission and the potential of these variants to circumvent immunity elicited by natural infection or vaccination.Keywords
Funding Information
- NIH Office of the Director (Undergraduate Scholarship Program)
- National Institute of Allergy and Infectious Diseases (Intramural Research Program of the Vaccine Researc)
- Office of Public Health Preparedness and Response (75A50120C00034)
This publication has 3 references indexed in Scilit:
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineThe New England Journal of Medicine, 2021
- Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older AdultsThe New England Journal of Medicine, 2020
- An mRNA Vaccine against SARS-CoV-2 — Preliminary ReportThe New England Journal of Medicine, 2020